Somewhat Favorable News Coverage Somewhat Unlikely to Affect Akebia Therapeutics (AKBA) Stock Price
News stories about Akebia Therapeutics (NASDAQ:AKBA) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akebia Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.0998308746615 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Royal Bank Of Canada Reiterates Outperform Rating for Akebia Therapeutics, Inc. (AKBA) (americanbankingnews.com)
- Akebia Therapeutics, Inc. (AKBA) Now Covered by Royal Bank Of Canada (americanbankingnews.com)
- Akebia (AKBA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference – Slideshow (seekingalpha.com)
- Ultragenyx’s Burosumab Positive in Phase II for XLH and TIO (finance.yahoo.com)
- Akebia Therapeutics : Stocks Under Scanner in the Biotech Space — Acorda Therapeutics, Advaxis, Xbiotech, and Akebia Therapeutics (4-traders.com)
Several research analysts have weighed in on AKBA shares. ValuEngine upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Aegis restated a “buy” rating on shares of Akebia Therapeutics in a report on Monday, June 5th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Akebia Therapeutics in a report on Tuesday, June 6th. Zacks Investment Research downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Finally, BidaskClub downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $21.25.
Shares of Akebia Therapeutics (NASDAQ:AKBA) opened at 17.30 on Monday. The stock’s market cap is $316.59 million. Akebia Therapeutics has a one year low of $7.16 and a one year high of $17.79. The stock has a 50 day moving average of $15.33 and a 200 day moving average of $12.94.
Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.36. The firm had revenue of $28.52 million during the quarter, compared to the consensus estimate of $26.50 million. On average, analysts forecast that Akebia Therapeutics will post ($2.68) EPS for the current year.
In other news, Director Muneer A. Satter purchased 1,034,482 shares of the company’s stock in a transaction that occurred on Wednesday, July 5th. The shares were bought at an average price of $14.50 per share, for a total transaction of $14,999,989.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Michel Dahan sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $15.00, for a total transaction of $75,000.00. Following the completion of the transaction, the senior vice president now owns 102,224 shares in the company, valued at approximately $1,533,360. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,544 shares of company stock worth $111,287. 8.67% of the stock is currently owned by company insiders.
About Akebia Therapeutics
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.